142 results
Page 2 of 8
424B5
ql8phoo6n5yu jqt
28 Apr 22
Prospectus supplement for primary offering
8:09am
8-K
EX-99.1
bmv8gnk09phtm6 08
12 Nov 21
Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS
6:30am
8-K
EX-99.1
fkk9u9p
4 Nov 21
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:40am
8-K
EX-99.1
86bjz
13 Sep 21
Other Events
7:08am
8-K
EX-99.1
x9vmvv2f jfjo
19 May 21
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
5:08pm
8-K
EX-99.1
gar1jqmy2k
19 Nov 20
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
9:09am
8-K
EX-99.1
cfb44fv ydh
9 Nov 20
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
5:11pm
8-K
EX-99.1
mzj61mkb6hs
5 Nov 20
Adaptimmune Reports Q3 Financial Results and Business Update
7:40am